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Abstract 
Objective: To compare the proportion of women receiving same-day long-acting reversible 
contraception (LARC) between two different models of contraceptive provision adapted from the 
Contraceptive CHOICE Project.  
Study Design: We used a controlled time-trend study design to compare 502 women receiving 
structured contraceptive counseling in addition to usual care (“Enhanced Care”) to 506 women 
receiving counseling plus healthcare provider education and cost support for LARC (“Complete 
CHOICE”) at three federally qualified health centers. We provided funds to health centers to 
ensure an “on-the-shelf” supply and no-cost LARC for uninsured women. We recorded the 
contraceptive method chosen after contraceptive counseling and the healthcare provider 
appointment as well as the contraceptive method received that day. Among women choosing 
LARC, we calculated proportions and performed Poisson regression with robust error variance to 
estimate relative risks for same-day insertion. 
Results: Participant demographics reflected the health center populations; 69% were black, 66% 
had a high school diploma or less, 57% were publicly insured, and 75% reported household 
income less than 101% federal poverty line. There were 153 (30.5%) women in “Enhanced Care” 
and 273 (54.0%) in “Complete CHOICE” who chose LARC (p<0.01). Among women who 
chose LARC (n=426), those in “Complete CHOICE” were more likely to receive a same-day 
insertion, 53.8% vs. 13.7% (RRadj 4.73; 95%CI 3.20-6.98) compared to “Enhanced Care.”   
Conclusions: A contraceptive care model that included healthcare provider education and cost 
support for LARC in addition to structured contraceptive counseling resulted in higher rates of 
same-day LARC insertion compared to contraceptive counseling and usual care alone.  
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Implications 
Contraceptive care provision which includes contraceptive counseling, healthcare provider 
education, and “on-the-shelf”, long-acting reversible contraception facilitate same-day initiation 
of these methods. Interventions that focus solely on contraceptive counseling do not address 
other structural barriers to same-day contraceptive provision of all methods including cost and 
provider practice. 
 
Keywords: Contraceptive counseling; long-acting reversible contraception; intrauterine device; 
contraceptive implant; same-day insertion   
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Introduction 
More than 40% of unintended pregnancies are the result of inconsistent contraceptive 
use.(1) Oral contraceptive pills (OCPs) and condoms require high levels of adherence from users, 
leading to typical-use failure rates of 7 and 13%, respectively.(2) In contrast, long-acting 
reversible contraception (LARC), which includes intrauterine devices (IUDs) and implants 
require little user adherence and have typical-use failure rates of 1%.(2) Despite their known 
effectiveness, LARC is used less frequently than OCPs and condoms. While not all women will 
prefer LARC, barriers such as out-of-pocket cost, healthcare provider misconceptions, and 
requirements for multiple visits to initiate LARC may limit access for women who desire these 
methods. One study found that women with an out-of-pocket cost less than $50 were more than 
11-times more likely to obtain an IUD than women required to pay $50 or more.(3) Several 
studies have shown that misconceptions among healthcare providers may incorrectly prevent 
some women, including adolescents, nulliparous women, and women with a history of sexually 
transmitted infections (STIs), from using IUDs.(4-6) Additional studies have identified 
requirements for patients to return for a second visit for placement of an IUD or implant as a 
barrier to these methods.(7, 8) 
Findings from the Contraceptive CHOICE Project demonstrated that removal of 
contraceptive barriers increased uptake of LARC and reduced unintended pregnancy.(9, 10) 
While the CHOICE Project was successful in a research setting, we had not tested the model of 
care in a community setting. We conducted a subsequent longitudinal study implementing two 
models of care adapted from the CHOICE Project in federally qualified health centers (FQHC); 
“Enhanced Care” which provided the CHOICE Project structured contraceptive counseling in 
addition to usual contraceptive care and “Complete CHOICE” which provided contraceptive 
counseling plus healthcare provider education, in-clinic stocking of LARC, and no-cost LARC 
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for uninsured patients. Our primary objective was to compare 12-month unintended pregnancy 
rates between the two groups. The objective of this analysis was to compare the proportion of 
women receiving same-day insertion at enrollment among those desiring LARC between 
“Enhanced Care” and “Complete CHOICE.” 
 
Material & Methods 
 We conducted this study in collaboration with three Midwest federally-qualified health 
centers (FQHC) which serve a predominantly low-income, minority urban population. The 
health centers were located in two states without Medicaid expansion through the Affordable 
Care Act. We used a controlled time-trend design to compare two different models of 
contraceptive provision. Controlled time-trend analysis is a nonrandomized study design where 
outcomes are compared before and after a change occurs in the healthcare setting.(11) We 
selected this study design rather than a randomized controlled trial in discussion with 
participating health centers as none were willing to be randomized to structured contraceptive 
counseling plus usual care (“Enhanced Care”). We used the National Institutes of Health 
Director’s Council of Public Representatives Community Engagement Plan as a framework to 
guide our partnership with the health centers.(12) 
Participating sites included two health centers belonging to the same organization and 
one health center affiliated with a separate organization. The three sites saw approximately 4,000 
unique reproductive-age women annually. Across the three health centers, there were 38 
healthcare providers; 13 family medicine, 10 nurse practitioners, 6 obstetrician-gynecologists, 
five pediatricians, and four internists. Of these, 16 were trained to place IUDs and implants and 
three were trained to place implants only. All sites also provided obstetric care. Prior to study 
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initiation, all health centers provided refillable methods of contraception such as OCPs and depo-
medroxyprogesterone acetate (DMPA). For uninsured patients, cost was determined using an 
income-based sliding fee scale. All health centers provided IUDs and implants, but few 
performed same-day insertion due to limited in-clinic inventory and health center practices such 
as requiring women to be on their menses or having results of testing for STIs prior to insertion. 
None of the three health care centers had a standardized approach to contraceptive counseling. 
The health centers did not keep detailed data about LARC use among their patient population. 
Therefore, we performed a cross-sectional survey of 241 randomly selected reproductive-aged 
female patients from the three sites, which found that 17.4% of respondents were currently using 
LARC.  
In the first group, “Enhanced Care,” women received the structured, patient-centered 
contraceptive counseling developed in the CHOICE Project (13) delivered by a trained health 
center staff member, in addition to usual contraceptive care. For the second group, “Complete 
CHOICE,” we added health care provider training and cost support for LARC to the counseling. 
Cost support included upfront funds for health centers to purchase an “on-the-shelf” supply of 
LARC to ensure methods were available for same day placement. Funds were also available to 
provide no-cost LARC for uninsured patients. These additional components represented the 
change in the system for the controlled time-trend design.  
We educated healthcare providers regarding evidence-based recommendations for 
contraception and potential barriers to same-day IUD and implant insertion.  The principal 
investigator conducted five, 60-minute educational group sessions and two one-on-one sessions 
to reach 32 healthcare providers across the three health centers.  All participating health centers 
had existing providers trained in IUD and implant provision. Educational sessions emphasized 
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the importance of patient autonomy and removing LARC on patient request. Health centers 
provided LARC removals using the health center’s existing sliding scale.  
Each health center identified an existing staff member to be the primary site 
contraceptive counselor and research assistant who was trained in the CHOICE Project 
contraceptive counseling and clinical research protocols by the Washington University research 
team. Additional staff members could be trained as desired by the health center. The CHOICE 
Project counseling model has previously been described in detail.(13)
 
Briefly, this counseling 
uses an effectiveness-based framework for presenting the most common reversible contraceptive 
methods. Counselors provided participants with a brief description of contraceptive method 
duration, instruction for use, and common side effects. Counseling sessions used the GATHER 
framework (14) and were personalized for each patient, accounting for individual preferences.      
The site counselor reviewed the health center schedules to identify potentially eligible 
patients. Recruitment focused primarily on women with reproductive health appointments, 
although we also approached family medicine and pediatric patients. Women were eligible to 
participate if they had a healthcare appointment at a participating health center, were between 
14-45 years of age, spoke English or Spanish, were not currently pregnant, were currently 
sexually active with a male partner or planned to become sexually active in the next 3 months, 
did not desire pregnancy in the next 12 months, and were at risk for unintended pregnancy (i.e. 
had not undergone sterilization or hysterectomy). Women who reported having one sexual 
partner who had undergone vasectomy were ineligible. Current LARC users were eligible to 
participate if they were seeking removal of their method, either because the method had expired 
or to switch to a different contraceptive method.  Women did not have to choose a method of 
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contraception to be eligible to participate.  Eligible participants provided written informed 
consent prior to participating in research activities.  
For both “Enhanced Care” and “Complete CHOICE,” the site counselor provided 
structured contraceptive counseling after obtaining informed consent. The site counselor then 
administered a baseline questionnaire, which collected demographic characteristics, reproductive 
history, current contraceptive method, and desired contraceptive method.  After the participant’s 
visit with the healthcare provider, the site counselor completed a post-appointment survey with 
the participant, which asked about contraceptive method chosen and whether the method was 
received during that visit. Participants received a gift card for participation.  We obtained 
approval from the Human Research Protection Office at the Washington University in St. Louis 
School of Medicine prior to participant recruitment. Parental consent was not required for 
participants under 18 years of age, as it is not required for adolescents to access confidential 
reproductive health services. We registered the study with ClinicalTrials.gov (NCT02364037). 
We performed data collection and management using REDCap electronic data capture 
tools.(15) Data analysis was performed using Stata 14 (StataCorp, College Station, TX).  We 
described demographic and reproductive characteristics using frequencies and compared 
“Enhanced Care” and “Complete CHOICE” using X2 and Fisher’s exact test as appropriate to 
assess for differences. Because characteristics differed between the two groups, we performed 
univariate Poisson regression with robust error variance to identify associations between baseline 
characteristics and our primary outcome of interest, same-day insertion of LARC. Poisson 
regression with robust error variance allows for a conservative estimation of the relative risk 
when the outcome of interest occurs more than 10% of the time.(16) We used multivariable 
Poisson regression to adjust for covariates associated with study group and the outcome of 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
interest in univariate models. We planned to include site in the regression model to control for 
any variability between sites. We defined confounding as any covariate significant at the 0.05 
level in the univariate models. We calculated the sample size based on the parent study’s primary 
outcome of unintended pregnancy at 12 months. Using an alpha of 0.05, the sample of 1,008 
women provided more than 99% power to determine an increase in same-day insertion from 10% 
to 20%.   
 
Results 
We approached 1,561 women between June 2014 and September 2015 for participation; 
81% had a scheduled obstetrics-gynecology appointment and 19% had a scheduled family 
medicine or pediatric appointment. We enrolled women into “Enhanced Care” between June 
2014 and February 2015 and “Complete CHOICE” between February and September 2015.  
There was no recruitment gap between the two groups. “Complete CHOICE” recruitment began 
immediately following the healthcare provider training session at each site and was initiated at 
the three sites within a two-week period. Figure 1 shows the study flow diagram. There were 
1,008 unique women enrolled, 502 women in “Enhanced Care” and 506 in “Complete CHOICE.” 
Eleven women who initially enrolled in “Enhanced Care” and subsequently crossed over to 
“Complete CHOICE” were included only in “Enhanced Care” for the analysis.   
Table 1 shows participant demographic and reproductive characteristics by group and 
health center. Overall, the majority of participants were black (68.8%), had a high school 
diploma or less (65.7%), had never been married (72.9%), were publicly insured (58.0%), and 
reported household income at or below the federal poverty level (76.0%). Women in “Complete 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
CHOICE” were older, more likely to be Hispanic and uninsured, and less likely to be black, 
single, or report a history of unintended pregnancy.   
Table 2 shows the contraceptive method used prior to enrollment, chosen at enrollment 
visit, and that the participant left with post-enrollment. Women in “Complete CHOICE” were 
more likely to choose LARC (54.9% vs. 30.5%, p<0.01) compared to “Enhanced Care.” Among 
women who chose LARC (n=426), 13.7% of “Enhanced Care” received the method at the 
enrollment visit compared to 53.8% of “Complete CHOICE” (p<0.01). Table 3 shows the 
univariate and multivariable Poisson regressions for the association between group, enrollment 
site, demographic characteristics, and same-day LARC receipt. Adjusting for site, educational 
level, interest in a new contraceptive method, and prior contraceptive use, women in “Complete 
CHOICE” were almost 5 times more likely to receive a same-day IUD or implant (RRadj 4.73; 
95%CI 3.20-6.98)  
Table 4 shows the reason for non-receipt of LARC at enrollment. Among women in 
“Enhanced Care,” the most common reasons were ordering the method from a third-party 
pharmacy (38.4%), returning with menses for insertion (19.2%), and scheduling a return 
appointment (18.4%). In “Complete CHOICE”, the most common reasons were not enough time 
for the insertion (participant 21.0%, provider 14.5%) and provider requiring additional medical 
services prior to insertion (12.1%).  
 
Discussion 
Our study found that health care provider education and cost support for LARC in 
addition to structured, contraceptive counseling resulted in higher same-day insertion compared 
to structured counseling in addition to usual care. The low rates of same-day LARC receipt 
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observed in “Enhanced Care” suggest that barriers, including cost, significantly impact patients’ 
access to their preferred contraceptive method. We also observed that use of a third-party 
pharmacy was a barrier for more than a third of patients in “Enhanced Care” as the method was 
not available on the appointment day. Furthermore, non-evidence based practices such as 
requiring a patient to have their menses or a negative STI testing result at the time of LARC 
insertion created additional barriers.  Even in “Complete CHOICE,” only 54% of women 
choosing LARC received it the same day. The most common reason that women did not receive 
their method was because the patient or provider did not have time. This indicates that, in 
addition to maintaining clinic LARC inventory, health centers may also need to address clinic 
flow to facilitate same-day insertion when desired.   
Uptake of LARC in this study was lower than the 75% observed in the CHOICE 
Project.(10) However, unlike the CHOICE Project, participants were not required to switch or 
even choose a method of contraception to participate. The 54% uptake of LARC among 
“Complete CHOICE” is slightly higher to that observed in other community-based interventions 
conducted in Utah (43%),(17) Colorado (31%),(18) and Planned Parenthood health centers 
(28%).(19) In addition, the community-based study conducted in Salt Lake City, UT found that 
participants were 2.5 times as likely to obtain LARC at their initial health center visit.(17) A 
pilot study in Georgia found that after implementation of evidence-based criteria for LARC 
insertion in public health clinics, more than half of women requesting LARC received it the same 
day.(20)  
Concerns around LARC uptake as a primary study outcome have been raised by 
members of the family planning community as this focus on LARC may increase the risk of 
coercive practices .(21) We chose LARC uptake as a secondary outcome as these models of 
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contraceptive care were based on the CHOICE Project, which emphasized reducing barriers to 
LARC. However, in this analysis, we specifically examined the proportion of women who 
desired LARC and were able to receive it the same day. Prior studies have demonstrated that 
requirements for multiple visits to obtain LARC create barriers for women and these barriers are 
likely to have greater impact for low-income women with fewer resources.  A recent study of 
community health center staff and clinicians found that more than half of respondents reported 
their health center required at least two visits for an IUD insertion and felt that contraception 
often takes a “back seat” in community health centers.(6) While it is critical to prioritize patients’ 
reproductive autonomy, it is also necessary to reduce structural barriers so that women can 
access their desired contraceptive method in a timely manner.  
Strengths of this study include broad inclusion criteria which allowed us to enroll a 
diverse cohort of women who reflect the population of women at greatest risk of unintended 
pregnancy.(22) In addition, we implemented the interventions in community health centers to 
make the findings as generalizable as possible. Limitations of our study include the lack of a 
randomized controlled trial design. There were significant differences between “Enhanced Care” 
and “Complete CHOICE” at baseline, and while we performed multivariable analyses to control 
for differences between the groups, there may have been unmeasured confounding.  
In summary, we successfully implemented two models of contraceptive care adapted 
from the CHOICE Project in the FQHC setting. We found that the model including provider 
education and cost support for LARC resulted in higher rates of same-day LARC insertion. 
While contraceptive counseling is a key component of clinical family planning encounters, 
interventions must also address other barriers to contraceptive access including provider training, 
on-the-shelf LARC, and cost to truly increase access for patients.  All methods of contraception, 
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regardless of the upfront cost, should be readily available to all women to allow them to obtain 
their preferred method.   
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Figure 1: Study flow and reasons for non-participation.  
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Table 1: Baseline demographic and reproductive characteristics of participants in Enhanced Care 
and Complete CHOICE groups stratified by health center 
 Health Center A Health Center B Health Center C 
Characteristic 
Enhan
ced 
Care 
(n=203
) 
N(%) 
Compl
ete 
CHOI
CE 
(n=162
)  
N(%) 
P 
Valu
e
*
 
Enhan
ced 
Care 
(n=129
) 
N(%) 
Compl
ete 
CHOI
CE 
(n=159
)  
N(%) 
P 
Valu
e
*
 
Enhan
ced 
Care 
(n=170
) 
N(%) 
Compl
ete 
CHOI
CE 
(n=185
)  
N(%) 
P 
Valu
e
*
 
Age   0.33   0.61   0.02 
14-19 years 33 
(16.3) 
33 
(20.4) 
 25 
(19.4) 
25 
(15.7) 
 30 
(17.7) 
34 
(18.4) 
 
20-29 years 132 
(65.0) 
93 
(57.4) 
 59 
(45.7) 
71 
(44.7) 
 96 
(56.5) 
80 
(43.2) 
 
30-45 years 38 
(18.7) 
36 
(22.2) 
 45 
(34.9) 
63 
(39.6) 
 44 
(25.9) 
71 
(38.4) 
 
Race   0.82   0.10   <0.0
1 
Black 201 
(99.0) 
160 
(98.8) 
 36 
(27.9) 
48 
(30.2) 
 137 
(80.6) 
112 
(60.5) 
 
White 2 (1.0) 2 (1.2)  74 
(57.4) 
100 
(62.9) 
 20 
(11.8) 
57 
(30.8) 
 
Other 0 (0.0) 0 (0.0)  19 
(14.7) 
11 
(6.9) 
 13 (7.7) 16 
(8.7) 
 
Hispanic   0.58   0.48   0.01 
Yes 6 (3.0) 8 (4.9)  22 
(17.1) 
31 
(19.5) 
 11 (6.5) 27 
(14.6) 
 
Missing 2 (1.0) 1 (0.6)  1 (0.8) 0 (0.0)  0 (0.0) 0 (0.0)  
Education   0.96   0.37   <0.0
1 
≤ High school 158 
(77.8) 
128 
(79.0) 
 82 
(63.6) 
106 
(66.7) 
 77 
(45.3) 
111 
(60.0) 
 
Some college 40 
(19.7) 
30 
(18.5) 
 35 
(27.1) 
45 
(28.3) 
 78 
(45.9) 
48 
(26.0) 
 
4+ years college 5 (2.5) 4 (2.5)  12 (9.3) 8 (5.0)  15 (8.8) 26 
(14.1) 
 
Marital status    0.32   0.01   0.04 
Never married 185 
(91.1) 
153 
(94.4) 
 92 
(71.3) 
84 
(52.8) 
 117 
(68.8) 
104 
(56.2) 
 
Married/living with 
partner 
15 (7.4) 6 (3.7)  32 
(24.8) 
64 
(40.3) 
 38 
(22.4) 
62 
(33.5) 
 
Separated/divorced/
widowed 
3 (1.5) 3 (1.9)  5 (3.9) 11 
(6.9) 
 15 (8.8) 19 
(10.3) 
 
Insurance status   0.27   0.02   0.23 
None 36 
(17.7) 
19 
(11.7) 
 35 
(27.1) 
68 
(42.8) 
 49 
(28.8) 
62 
(33.5) 
 
Public 150 
(73.9) 
130 
(80.3) 
 72 
(55.8) 
67 
(42.1) 
 89 
(52.4) 
77 
(41.6) 
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Commercial 17 (8.4) 13 
(8.0) 
 22 
(17.1) 
24 
(15.1) 
 31 
(18.2) 
45 
(24.3) 
 
Missing 0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  1 (0.6) 1 (0.5)  
Federal poverty level   0.68   0.90   0.22 
≤ 100% 164 
(80.8) 
134 
(82.7) 
 94 
(72.9) 
113 
(71.2) 
 124 
(72.9) 
137 
(74.1) 
 
101%-200% 34 
(16.8) 
26 
(16.1) 
 30 
(23.4) 
38 
(23.9) 
 38 
(22.4) 
31 
(16.8) 
 
≥ 201% 5 (2.5) 2 (1.2)  3 (2.3) 6 (3.8)  8 (4.7) 16 
(8.7) 
 
Missing 0 (0.0) 0 (0.0)  2 (1.6) 2 (1.3)  0 (0.0) 1 (0.5)  
Parity   0.95   0.23   0.15 
0 53 
(26.1) 
41 
(25.3) 
 45 
(34.9) 
51 
(32.1) 
 63 
(37.1) 
73 
(39.5) 
 
1-2 99 
(48.8) 
78 
(48.2) 
 63 
(48.8) 
 69 
(43.4) 
 83 
(48.8) 
74 
(40.0) 
 
3+ 51 
(25.1) 
43 
(26.5) 
 21 
(16.3) 
39 
(24.5) 
 24 
(14.1) 
38 
(20.5) 
 
History of a prior 
unintended 
pregnancy 
  0.15   0.54   0.09 
Yes 92 
(45.3) 
57 
(35.2) 
 76 
(58.9) 
88 
(55.4) 
 89 
(52.4) 
77 
(41.6) 
 
Missing 1 (0.5) 1 (0.6)  0 (0.0) 0 (0.0)  0 (0.0) 1 (0.5)  
Plan for future 
children 
  0.01   <0.0
1 
  0.02 
In the next 1-3 years 30 
(14.8) 
25 
(15.4) 
 19 
(14.7) 
24 
(15.1) 
 37 
(21.8) 
27 
(14.6) 
 
In the next 4-5 years 32 
(15.8) 
22 
(13.6) 
 16 
(12.4) 
31 
(19.5) 
 38 
(22.4) 
27 
(14.6) 
 
In more than 5 years 51 
(25.1) 
19 
(11.7) 
 57 
(44.2) 
31 
(19.5) 
 36 
(21.2) 
40 
(21.6) 
 
        Not planning to 
have (more) children 
88 
(43.4) 
96 
(59.3) 
 37 
(28.7) 
73 
(45.9) 
 59 
(34.7) 
91 
(49.2) 
 
Missing 2 (1.0) 0 (0.0)  0 (0.0) 0 (0.0)  0 (0.0) 0 (0.0)  
Feeling if got 
pregnant in the next 
12 months 
  0.09   0.32   <0.0
1 
Upset 129 
(63.6) 
97 
(59.9) 
 82 
(63.6) 
90 
(56.6) 
 111 
(65.3) 
106 
(57.3) 
 
Neutral 45 
(22.2) 
26 
(16.1) 
 23 
(17.8) 
35 
(22.0) 
 34 
(20.0) 
40 
(21.6) 
 
Pleased 14 (6.9) 20 
(12.4) 
 11 (8.5) 22 
(13.8) 
 24 
(14.1) 
18 
(9.7) 
 
Unsure 15 (7.4) 19 
(11.7) 
 13 
(10.1) 
12 
(7.6) 
 1 (0.6) 21 
(11.4) 
 
*2 used to estimate p values except for “Contraceptive method prior to enrollment” where Fisher’s exact test was 
used 
LARC – long acting reversible contraceptive; DMPA – depot medroxyprogesterone acetate; OCP – oral 
contraceptive pills
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Table 2: Contraceptive method used prior to enrollment visit, desired at end of enrollment, and 
left with at end of enrollment visit for “Enhanced Care” and “Complete CHOICE” groups. 
 
Pre-Enrollment 
Contraceptive Method 
Desired Contraceptive 
Method 
Contraceptive Method  
At End of Visit* 
 
Enhanc
ed Care 
(n=502) 
N(%) 
Comple
te 
CHOIC
E 
(n=506)  
N(%) 
P 
Valu
e 
Enhanc
ed Care 
(n=502) 
N(%) 
Comple
te 
CHOIC
E 
(n=506)  
N(%) 
P 
Valu
e 
Enhanc
ed Care 
(n=502) 
N(%) 
Comple
te 
CHOIC
E 
(n=506)  
N(%) 
P 
Valu
e 
Contraceptiv
e method 
  <0.0
1 
  <0.0
1 
  <0.0
1 
Hormonal 
IUD 
11 (2.2) 15 (3.0)  
41 (8.2) 
85 
(16.8) 
 10 (2.0) 40 (7.9)  
Copper IUD 0 (0.0) 8 (1.6)  27 (5.4) 26 (5.1)  2 (0.4) 11 (2.2)  
Implant 8 (1.6) 23 (4.6)  
85 (16.9) 
162 
(32.0) 
 17 (3.4) 110 
(21.7) 
 
DMPA 185 
(36.9) 
125 
(24.7) 
 192 
(38.3) 
127 
(25.1) 
 220 
(43.8) 
145 
(28.7) 
 
OCP/patch/ri
ng 
67 (13.4) 37 (7.3)  104 
(20.7) 
53 
(10.5) 
 113 
(22.5) 
66 
(13.0) 
 
Condoms 46 (9.2) 77 
(15.2) 
 
13 (2.6) 16 (3.2) 
 35 (7.0) 57 
(11.3) 
 
Other 19 (3.8) 15 (3.0)  5 (1.0) 2 (0.4)  13 (2.6) 8 (1.6)  
Nothing 166 
(33.1) 
206 
(40.7) 
 
35 (7.0) 35 (6.9) 
 92 (18.3) 69 
(13.6) 
 
IUD – Intrauterine device; DMPA – depot medroxyprogesterone acetate; OCP – oral contraceptive pills 
*There were 22 existing LARC users (8 in “Enhanced Care” and 14 in “Complete CHOICE”) who did not chose a 
new method or desired a new LARC but did not receive on the day of enrollment; therefore 21 in “Enhanced Care” 
and 149 in “Complete CHOICE” actually received a LARC insertion at the enrollment visit.  
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Table 3: Participant characteristics associated with same-day insertion of long-acting reversible 
contraception at enrollment visit. 
  Univariate Analysis Multivariable 
Analysis* 
(N=426) 
Baseline Characteristic N RR (95% CI) RR (95% CI) 
Group 426    
Enhanced Care  Ref. Ref. 
Complete CHOICE   3.92 (2.60-5.93) 4.73 (3.20-6.98) 
Enrollment site 426   
Health Center A  Ref. Ref. 
Health Center B  0.88 (0.64-1.20) 0.55 (0.42-0.71) 
Health Center C  0.90 (0.67-1.21) 0.55 (0.42-0.72) 
Age 426    
14-19 years  1.06 (0.76-1.47) --- 
20-29 years  Ref. --- 
30-45 years  1.08 (0.83-1.41) --- 
Race 426    
Black  0.94 (0.74-1.21) --- 
White  Ref. --- 
Other  0.81 (0.47-1.39) --- 
Hispanic 425 1.03 (0.75-1.43) --- 
Education 426   
≤ High school  1.53 (1.10-2.12) 1.43 (1.06-1.91) 
Some college  Ref. Ref. 
4+ years college  1.28 (0.77-2.14) 1.25 (0.79-1.98) 
Marital status  426    
Never married  Ref. --- 
Married/living with partner  0.95 (0.73-1.25) --- 
Separated/divorced/widowed  0.93 (0.58-1.50) --- 
Insurance status 426    
None  1.10 (0.85-1.42) --- 
Public  Ref. --- 
Commercial  0.99 (0.70-1.41) --- 
Federal Poverty Level 425   
≤ 100%  Ref. --- 
101%-200%  0.85 (0.61-1.20) --- 
≥ 201%  0.61 (0.28-1.31) --- 
Parity 426   
0  Ref. --- 
1-2  1.04 (0.78-1.37) --- 
3+  1.01 (0.72-1.41) --- 
History of unintended 
pregnancy 
424 0.90 (0.71-1.13) --- 
Plan for future children 425   
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In the next 1-3 years  0.90 (0.60-1.36) --- 
In the next 4-5 years  0.97 (0.70-1.34) --- 
In more than 5 years  0.91 (0.68-1.23) --- 
        Not planning to have 
(more) children 
 Ref. --- 
Feeling if got pregnant in the 
next 12 months 
426   
Upset  Ref. --- 
Neutral  1.04 (0.77-1.42) --- 
Pleased  0.96 (0.61-1.51) --- 
Unsure  1.15 (0.77-1.70) --- 
Interest in a new contraceptive 
method 
426 0.53 (0.41-0.69) 0.76 (0.49-1.16) 
Contraceptive method prior to 
enrollment 
426   
LARC  1.39 (1.05-1.85) 1.11 (0.74-1.67) 
DMPA  0.64 (0.43-0.97) 0.69 (0.48-0.98) 
OCP/patch/ring  0.78 (0.48-1.28) 0.98 (0.64-1.50) 
Condoms  0.84 (0.58-1.21) 0.90 (0.63-1.27) 
Other  0.64 (0.32-1.30) 0.81 (0.43-1.50) 
Nothing  Ref. Ref. 
*Adjusted for site, education level, interest in a new contraceptive method, and prior contraceptive use. 
RR were calculated using univariate and multivariable Poisson regression of association between group assignment 
and baseline characteristics. 
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Table 4: Reasons for non-receipt of desired long-acting reversible contraception on enrollment 
day for participants in “Enhanced Care” and “Complete CHOICE” groups. 
 Enhanced Care 
N=125* 
Complete CHOICE 
N=124 
Reason N(%) N(%) 
Return for insertion after device ordered from 
3
rd
 party pharmacy 
48 (38.4) 1 (0.8) 
Return for insertion with menses 24 (19.2) 12 (9.7) 
Provider wanted participant to think about 
decision or return for another appointment 
23 (18.4) 15 (12.1) 
Check insurance coverage 12 (9.6) 0 (0.0) 
Return for insertion after results of sexually 
tranmistted infection testing 
8 (6.4) 1 (0.8) 
Participant wanted more time to think about 
decision 
6 (4.8) 10 (8.1) 
Participant didn’t have time for insertion 1 (0.8) 26 (21.0) 
Provider didn’t have time for insertion 0 (0.0) 18 (14.5) 
Appointment needs to be scheduled with 
provider trained trained to place IUD/implant 
0 (0.0) 7 (5.7) 
Provider requires additional medical 
evaluation before insertion 
0 (0.0) 6 (4.8) 
Participant is less than 6 weeks postpartum 0 (0.0) 5 (4.0) 
Could not reliably rule out pregnancy  0 (0.0) 3 (2.4) 
Participant needs cervical ripening for 
insertion 
0 (0.0) 3 (2.4) 
Recent history of sexually tranmistted 
infection 
0 (0.0) 3 (2.4) 
Participant wants to discuss with partner 0 (0.0) 2 (1.6) 
Other 2 (1.6) 4 (3.2) 
* 3 women had no plan, total is 128   
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